A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology

(2012) Sara L. Bissett et al.   Clinical and Vaccine Immunology

Understanding and learning from the success of prophylactic human papillomavirus vaccines

(2012) John T. Schiller et al.   NATURE REVIEWS MICROBIOLOGY

Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers

(2012) Zhiming Huo et al.   PLoS One

Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation

(2012) Rebecca Howell-Jones et al.   VACCINE

Worldwide burden of cervical cancer in 2008

(2011) M. Arbyn et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

(2011) Beibei Lu et al.   BMC INFECTIOUS DISEASES

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial

(2011) Mel Krajden et al.   Clinical and Vaccine Immunology

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

(2011) Tino F. Schwarz et al.   Human vaccines & immunotherapeutics

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

(2011) Barbara Romanowski   Human vaccines & immunotherapeutics

The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay

(2011) Darron R. Brown et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection

(2011) S. Longet et al.   JOURNAL OF VIROLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Prevalence of Human Papillomavirus Antibodies in Males and Females in England

(2011) Sarika Desai et al.   SEXUALLY TRANSMITTED DISEASES

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

(2011) Eve Draper et al.   VACCINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England

(2010) R Howell-Jones et al.   BRITISH JOURNAL OF CANCER

In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection

(2010) Patricia M. Day et al.   Cell Host & Microbe

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology

Potential mechanisms for HPV vaccine-induced long-term protection

(2010) Margaret Stanley   GYNECOLOGIC ONCOLOGY

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

(2010) Hans-Ulrich Bernard et al.   VIROLOGY

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

A review of human carcinogens—Part B: biological agents

(2009) Véronique Bouvard et al.   LANCET ONCOLOGY

Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]

(2008) Susan J Keam et al.   DRUGS

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

(2008) Tiina Petäjä et al.   JOURNAL OF ADOLESCENT HEALTH

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

(2008) Troy J. Kemp et al.   VACCINE